In summary, based on this preclinical and translational data, we hypothesized that inhibition of AURKA in endocrine-resistant breast cancer could lead to a new therapeutic strategy to restore endocrine sensitivity by targeting the CD44+/CD24low/−/ERαlow/− tumor-initiating cells that promote endocrine resistance. This evidence concerns the gene CD44 and breast cancer.